Rachel brings over 20 years’ expertise in autoimmune research to Viela Bio. Most recently, Rachel was a Principal Scientist in the Respiratory, Inflammation, and Autoimmunity group at MedImmune. She joined MedImmune in 2008 from the National Institutes of Health where she spent several years studying immune mediators driving autoimmunity. Rachel received her PhD from Boston University School of Medicine, was a Postdoctoral fellow at Stanford University School of Medicine, and a Scientific Member at Basel Institute for Immunology. Rachel has authored over 40 research manuscripts.
RESEARCH & DEVELOPMENT LEADERSHIP
Gábor brings over 20 years of combined academic and biopharmaceutical clinical development expertise in systemic autoimmune disease. He joined MedImmune in 2012 from the NIH after a 15 years career as an academic rheumatologist focusing on clinical studies in systemic lupus erythematosus (SLE) and Sjögren’s syndrome. At MedImmune he served as Director and then Senior Director for Respiratory, Inflammation and Autoimmunity and oversaw clinical development of several assets in systemic autoimmune diseases. Most recently he served as Program Development Lead for Neurodegenerative Diseases at Regenxbio.
Gábor received an MD degree from the University Medical School of Pécs, Hungary, a PhD in clinical immunology from Semmelweis University, Budapest, Hungary and a Masters of Health Sciences – Clinical Research degree from Duke University. He completed his medical residency at SUNY Stony Brook and a rheumatology fellowship at the NIH. He is an author on over 100 peer reviewed publications.
Dr. Katz brings 30 years of combined biopharmaceutical and academic career in the areas of immunology and immune induced diseases, and organ transplantation. Most recently, Dr. Katz served as a senior director for respiratory, inflammation, and autoimmunity, at MedImmune, where he oversaw clinical development in neuro-inflammation, inflammatory bowel disease, and myositis. Before joining MedImmune Dr. Katz was vice president at CTI clinical trial and consulting services, and senior director at Medicine Development Group, Pfizer Inc. Dr. Katz joined the pharmaceutical industry in 2004 following a 20 years of academic career as a liver transplant surgeon. His last position in academia was associate professor of surgery and director of liver transplant at University of Massachusetts Medical Center. Dr. Katz earned his MD degree from the Hebrew University-Hadassah Medical School in Jerusalem Israel. Dr. Katz is an author in more than 50 peer review publications.
Ted brings more than two decades of experience in clinical operations involving a wide range of therapeutic areas. Most recently, Ted was Senior Director, Clinical Operations Head, MedImmune, where he led the clinical operations group of Respiratory, Inflammation, Autoimmune, Cardiovascular and Metabolic disease. Ted joined MedImmune in 2009 from UCB Pharma, where he was an Associate Director, Clinical Development in the Inflammation and Autoimmune therapeutic area. Ted started his research career at the Bedford Veteran’s Administration Medical Center, before joining a CRO. Ted earned his BA in Legal Studies from the University of Massachusetts, Amherst.
Bill joins Viela Bio after 3 years at MedImmune as a Principal Scientist in the department of Translational Medicine, where he led Translational Sciences and Personalized Medicine efforts for several early and late stage programs in rheumatologic, respiratory and gastroenterological autoimmune diseases. Prior to that Bill led a team supporting biomarker discovery, development and clinical execution for several preclinical, Ph1 and Ph2 programs for 10 years in the Department of Molecular Sciences at Amgen. Bill studied the physical origins of basic adaptive immunity as a post-doctoral fellow at the National Jewish Health in Denver, after receiving his PhD studying biophysics at the University of Oregon Institute of Molecular Biology.
Dewei brings more than 15 years of experience in drug development and clinical research across different therapeutic areas (Infectious Disease/Vaccine, Oncology, Cardiovascular Disease, Respiratory, Inflammation, and Autoimmune). Most recently, Dewei was a Statistical Science Director at MedImmune, where he led statistical efforts in the development of compounds across various disease areas. Before he joined MedImmune in 2009 as a Senior Principal Statistician, Dewei was a Senior Statistician at EMMES Corporation. Dewei received his Ph.D. in Biostatistics from the George Washington University and a MS in Biology from Georgetown University.